Court of Appeals for the D.C. Circuit June 3, 2005, 05-5004 (Teva Pharmaceutical Industries Ltd. v. Crawford)

Also known as

United States · · · 03-06-2005

United States Court of Appeals

FOR THE DISTRICT OF COLUMBIA CIRCUIT

Argued May 9, 2005 Decided June 3, 2005

No. 05-5004

TEVA PHARMACEUTICAL INDUSTRIES LTD . AND

TEVA PHARMACEUTICALS, USA, INC.,

APPELLANTS

v.

LESTER M. CRAWFORD, JR., ACTING COMMISSIONER OF FOOD

AND DRUGS, ET AL.,

APPELLEES

Appeal from the United States District Court

for the District of Columbia

(No. 04cv01416)

William H. Rooney argued the cause for appellants.

With him on the briefs were Theodore C. Whitehouse and James

N. Czaban.

William A. Rakoczy, Christine J. Siwik, Amy D. Brody,

and Lara E. Monroe-Sampson were on the brief for amicus

curiae Mylan Pharmaceuticals, Inc. in support of appellants.

Jeffrey S. Bucholtz, Deputy Assistant Attorney General,

U.S. Department of Justice, argued the cause for federal

appellees. With him on the brief were Peter D. Keisler,

2

Assistant Attorney General, Eugene M. Thirolf, Director,

Andrew E. Clark, Attorney, Alex M. Azar, II, General Counsel,

Food & Drug Administration, and Eric M. Blumberg, Deputy

Chief Counsel.

Bert W. Rein argued the cause for appellees Pfizer Inc.,

et al. With him on the brief were Karyn K. Ablin and Jeffrey B.

Chasnow.

Before: GINSBURG , Chief Judge, and SENTELLE and

ROGERS, Circuit Judges.

Opinion for the Court filed by Chief Judge GINSBURG.

GINSBURG, Chief Judge: Teva Pharmaceutical Industries

has sued to overturn the Food and Drug Administration’s denial

of its “citizen petition” requesting that the agency prohibit

Pfizer, Inc., the holder of the approved New Drug Application

(NDA) for gabapentin, from marketing that drug in “generic”

form during the 180-day exclusivity period provided by the

Drug Price Competition and Patent Term Restoration Act, also

known as the “Hatch-Waxman Amendments” to the Food, Drug,

& Cosmetic Act. Because the exclusivity provision does not

apply to the holder of an approved NDA, the district court

entered a summary judgment for the FDA, which we now

affirm.

I. Background

Section 355(j) of 21 U.S.C.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.